Form 8-K for KITE PHARMA, INC.
Other Events, Financial Statements and Exhibits
patent license agreement (the “License”) with the National Institutes of Health (“NIH”). Pursuant to the License, Kite holds an exclusive, worldwide license to certain intellectual property related to T cell receptor-based product candidates that target MAGE A3 and A3/A6 antigens. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The following exhibit is filed as part of this Current Report:
99.1 Press Release of Kite issued October 20, 2015.